Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 06, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,407.79 pence per share.
- Treasury Holdings: Following the purchase, GSK holds 249,672,678 shares in Treasury.
- Shares in Issue: 5,748,594,734 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 750,000 shares on February 06, 2007. These shares are intended to be held in Treasury. The filing does not provide comparative data against prior periods for operational or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 750,000 shares by the price of 1,407.79 pence.
- Confirm the updated total voting rights denominator of 5,748,594,734 shares for disclosure threshold calculations under Financial Services Authority rules.
- Note that the company's Treasury share count has increased to 249,672,678 shares.
- Recognize that this filing is a regulatory disclosure of a capital transaction and does not contain operational performance data.